导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 17.21% | 362/4773 |
| 近一周 | -2.62% | 2703/5462 |
| 近一月 | -7.33% | 3786/5421 |
| 近一季 | -13.72% | 4068/5209 |
| 近半年 | 14.12% | 320/4920 |
| 近一年 | 24.43% | 298/4366 |
| 近两年 | 141.81% | 251/2954 |
| 近三年 | 111.81% | 101/2253 |
| 成立以来 | 201.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.88% 2942/4961 |
58.63% 423/5312 |
- - |
- - |
| 2025 | 55.05% 340/4813 |
-1.39% 2655/3635 |
2.88% 1291/4076 |
51.07% 284/4524 |
1.17% 1491/4813 |
| 2024 | 19.25% 540/3463 |
-1.51% 1236/2808 |
1.78% 447/3014 |
14.17% 2034/3129 |
4.19% 733/3463 |
| 2023 | 1.15% 369/2656 |
19.61% 138/2280 |
-1.06% 440/2385 |
-11.55% 2073/2515 |
-3.36% 666/2655 |
| 2022 | -30.27% 1628/2207 |
-23.29% 1727/1919 |
3.15% 1205/2016 |
-15.09% 1212/2113 |
3.79% 643/2208 |
| 2021 | 9.33% 457/1822 |
-5.91% 964/1255 |
15.38% 226/1330 |
-8.19% 1114/1466 |
9.69% 113/1822 |
| 2020 | 36.96% 386/1250 |
-2.85% 276/1028 |
27.39% 130/1067 |
3.20% 993/1164 |
7.24% 722/1184 |
| 2019 | 58.10% 60/1092 |
41.34% 43/754 |
-10.38% 735/804 |
12.68% 31/850 |
10.76% 98/918 |
| 2018 | -39.57% 610/834 |
- - |
- - |
- - |
-14.48% 586/691 |
| 2017 | 15.89% 242/714 |
- - |
- - |
- - |
- - |
| 2016 | -24.75% 478/605 |
- - |
- - |
- - |
- - |
| 2015 | 50.12% 20/575 |
- - |
- - |
- - |
- - |
| 2014 | 9.26% 211/237 |
- - |
- - |
- - |
- - |
| 2013 | 47.98% 5/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.34% 98/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商深证TMT50ETF联接A VS. 长安沪深300非周期A(740101) |